PURINE METABOLISM DISORDERS AS A PREDICTOR OF TYPE 2 DIABETES MELLITUS IN THE POPULATION

Authors

  • Chernyaeva A. O. Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv; State Institution «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Mykytyuk M. R. Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv; State Institution «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Karachentsev Yu. I. Kharkiv Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine, Kharkiv; State Institution «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Dorosh O. G. State Institution «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
  • Ashurov E. M. State Institution «V. Danilevsky Institute for Endocrine Pathology Problems National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2020.3.11

Keywords:

purine metabolism, impaired glucose homeostasis, type 2 diabetes mellitus, metabolic syndrome, uric acid.

Abstract

To determine the significance of hyperuricemia (HU) as a predictor of type 2 diabetes mellitus (DM) in apparently healthy (according to epidemiological criteria) individuals, an analysis of the relationship between elevated uric acid (UA) in the blood and all components of the metabolic syndrome (MS) was performed in randomized population samples. Material and methods. The reporting panel was formed according to the generally accepted epidemiological approach by the randomized sampling of the workers and employees of the industrial enterprise (n = 727 people). The age of the subjects ranged from 18 to 65 years; the average age was (38.13 ± 5.1) years. MS was confirmed by the IDF criteria. The glucose homeostasis condition was assessed according to the ADA recommendations. The purine metabolites were studied by the S. V. Oreshnikov et al. method (2008). The levels of uric acid were determined by the colorimetric method, xanthine oxidase activity by the photometric method. Anthropometric parameters, glycemia, immunoreactive insulin, blood lipid profile were studied, blood pressure was measured. Results and their discussion. In a random population sample, impaired glucose homeostasis was diagnosed in 11.8 % of subjects (including those with type 2 diabetes in 3.03 % cases, impaired glucose tolerance 6.50 %, fasting hyperglycemia 0.96 %, respectively). It was found that for each diagnosed earlier patient with type 2 diabetes, about three cases of type 2 diabetes de novo (ratio 1 : 2.75) are revealed, which confirms the feasibility of more active screening of the population for type 2 DM. Asymptomatic hyperuricemia was diagnosed in 16.2 % of the examined subjects. Positive statistically significant linear associations of the concentration of purine metabolism intermediates among them and UA with xanthine oxidase activity indicate a predominantly metabolic nature of hyperuricemia in the subjects of the randomized sample. The relative risk of impaired glucose homeostasis in subjects with established hyperuricemia is found to be 5.09 (95 % CI (3.82–6.79), type 2 diabetes 3.7 (95 % CI (2.28–6.02) Among all components of MS, the statistical value of hyperuricemia as a risk factor is the most significant for the disorders of glucose homeostasis (type 2 diabetes and impaired glucose tolerance (CA = 0.64).

References

Van der Schaft N, Brahimaj A, Wen KX, et al. PLoS One 2017; 12(6): e0179482. https://doi.org/10.1371/journal.pone.0179482.

Bombelli M, Quarti-Trevano F, Tadic M, et al. J Hyper- tens 2018; 36(7): 1492-1498. https://doi.org/10.1097/HJH.0000000000001721.

Dehghan A, van Hoek M, Sijbrands EJ, et al. Diabetes Care 2008; 31(2): 361-362. https://doi.org/10.2337/dc07-1276.

Wang T, Bi Y, Xu M, et al. Endocrine 2011; 40(1): 109- 116. https://doi.org/10.1007/s12020-011-9449-2.

Wu AH, Gladden JD, Ahmed M, et al. Int J Cardiol 2016; 213: 4-7. https://doi.org/10.1016/j.ijcard.2015.08.110.

Bardin T, Richette P. BMC Med 2017; 15(1): 123. https://doi.org/10.1186/s12916-017-0890-9.

McCracken E, Monaghan M, Sreenivasan S. Clin Der- matol 2018; 36(1): 14-20. https://doi.org/10.1016/j.clindermatol.2017.09.004.

Gluvic Z, Zaric B, Resanovic I, et al. Curr Vasc Pharmacol 2017; 15(1): 30-39. https://doi.org/10.2174/1570161114666161007164510.

WHO. Obesity: Preventing and managing the global epidemic : Report of a WHO Consultation, Geneva, 2000: 252 p.

Alberti KG, Eckel RH, Grundyet SM, et al. Circulation 2009; 120: 1640-1645.

American Diabetes Association. Diabetes Care 2012; 35(1): S.64-S.71.

HOMA Calculator. The Oxford Centre for Diabetes, Endocrinilogy and Metabolism, available at: http://www.dtu.ox.ac.uk/homacalculator/index.php.

Klimov AN, Nikul'cheva JuG. Obmen lipidov i lipoproteidov i ih narushenija, Sankt-Peterburg, 1999: 505 p.

ESC/ESH Guidelines for the management of arterial hypertension. Rev Esp Cardiol (Engl Ed) 2019; 72(2): 160. https://doi.org/10.1016/j.rec.2018.12.004.

Mallat SG, Kattar S, Tanios BY, et al. Curr Hypertens Rep 2016; 18(10): 74. https://doi.org/10.1007/s11906-016-0684-z.

Henning RJ. Future Cardiol 2018; 14(6): 491-509. https://doi.org/10.2217/fca-2018-0045.

Kuwabara M, Kuwabara R, Hisatome I, et al. J Obesity (Silver Spring) 2017; 25(11): 1997-2008. https://doi.org/10.1002/oby.22000.

Hou YL, Yang XL, Wang CX, et al. Lipids Health Dis 2019; 18(1): 81. https://doi.org/10.1186/s12944-019-1031-6.

Li L, Song Q, Yang X. J Diabetes Res 2019; 4: 29. https://doi.org/10.1155/2019/3175418.

Ali N, Perveen R, Rahman S, et al. PLoS One 2018; 13(11): e0206850. https://doi.org/10.1371/journal.pone.0206850.

Downloads

Published

2021-08-17

How to Cite

Chernyaeva, A. O., Mykytyuk, M. R., Karachentsev, Y. I., Dorosh, O. G., & Ashurov, E. M. (2021). PURINE METABOLISM DISORDERS AS A PREDICTOR OF TYPE 2 DIABETES MELLITUS IN THE POPULATION . Problems of Endocrine Pathology, 73(3), 89-97. https://doi.org/10.21856/j-PEP.2020.3.11

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 > >>